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This is to be compared with a previous era when small numbers of patients were investigated in order to select a dose for a phase III trial, e.g. in GUSTO 2 ,100 patients were tested with the streptokinase-tissue plasminogen activator (tPA) combination, and in GUSTO IIa ,50 patients were tested with the hirudin dose that was evaluated in GUSTO IIa. 3 The patients enrolled in SEPIA-ACS1 4 were at high risk for ischaemia (ST deviation 0.1 mV in the UFH plus eptifibatide group 57%, elevated biomarker in the UFH plus eptifibatide group 79%) and underwent a planned early invasive strategy. The primary endpoint was a composite of death, myocardial infarction (MI), urgent revascularization, and bail-out IIb/IIIa antagonists for an ischaemic or thrombotic endpoint.
Five doses of otamixaban were tested (0.08 mg/kg bolus followed by infusions of 0.035, 0.070, 0.105, 0.140, or 0.175 mg/kg/h) or a control of UFH plus eptifibatide with a single bolus of eptifibatide rather than two boluses: 180 mg/kg and infusion for 18-24 h with renal adjustment. This is different from the double bolus 180 mg/kg 10 min apart used in the ESPIRT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) 5 Also is there an acceptable ceiling for major bleeding? The Table 1 shows rates of TIMI major bleeding in recent trials. In the EARLY ACS trial TIMI major bleeding with upstream eptifibatide was 2.6% at 120 h vs. 1.8% for patients who received eptifibatide in the catheterization laboratory. 6 Clearly we need a common template to be available so trials can be compared. There is also a need to have reversible agents so that, once present, bleeding can be stopped. Bleeding is associated with increased morbidity and mortality (OASIS 5) 7 and it would seem reasonable to test a dose with decreased bleeding compared with control. Clearly there is much to be gained in capturing minor bleeding, but for selection of a drug dose to move into phase III trials, perhaps we should be more focused on what is a ceiling for unacceptable bleeding. This ceiling may be gleaned from major bleeding data The 0.035 mg/kg/h dose was stopped because of clinical evidence of inadequate anticoagulation. The primary endpoint was reduced from 6.2% in the combined UFH plus eptifibatide arm to 4.6, 3.8, 3.6, and 4.3% (P trend ¼ 0.34) for the four doses of otamixaban respectively. For death and MI there was a similar 42 -48% reduction for the otamixaban doses (2.8, 2.6, 2.7, and 2.8%) compared with UFH plus eptifibatide.
Rates of the primary safety endpoint of TIMI major and minor bleeding across the five otamixaban doses were 1.6, 1.6, 3.1, 3.4, and 5.4% (P trend ¼ 0.0001); the rate in the control arm was 2.7%.
Patients treated with 0.070 mg/kg/h tended to have higher rates of bail-out glycoprotein IIb/IIIa inhibitor; 1.99 (95% CI 0.73-5.44), whereas higher doses of otamixaban had similar use to that observed with UFH plus eptifibatide.
In SEPIA-PCI there were eight catheter thromboses. 1 Perhaps supplemental UFH should be considered to prevent contact thrombosis with otamixaban as with the indirect factor X inhibitor fondaparinux (OASIS 5, OASIS 6). It would be interesting to know how many cases of new intracoronary, catheter, or guidewire thrombus occurred in the current trial. MI was part of the composite endpoint and used the universal definition for MI and PCI, 8 but not for CABG, where only 5-fold elevation of biomarkers or new Q waves was required and not both, or evidence of new graft or native coronary artery occlusion. The universal redefinition of MI recommended that a universal definition template be available with different definitions and cut-off points for biomarkers, and hopefully that will be available online, so we can make comparisons with other trials. 
